MX2016009896A - Heteroaril amidas como inhibidores de agregacion de proteina. - Google Patents
Heteroaril amidas como inhibidores de agregacion de proteina.Info
- Publication number
- MX2016009896A MX2016009896A MX2016009896A MX2016009896A MX2016009896A MX 2016009896 A MX2016009896 A MX 2016009896A MX 2016009896 A MX2016009896 A MX 2016009896A MX 2016009896 A MX2016009896 A MX 2016009896A MX 2016009896 A MX2016009896 A MX 2016009896A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- protein aggregation
- methods
- heteroarly
- amides
- Prior art date
Links
- 230000004845 protein aggregation Effects 0.000 title abstract 3
- 150000001408 amides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 heteroaryl amide compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933246P | 2014-01-29 | 2014-01-29 | |
| US201462078895P | 2014-11-12 | 2014-11-12 | |
| PCT/US2015/013263 WO2015116663A1 (en) | 2014-01-29 | 2015-01-28 | Heteroarly amides as inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016009896A true MX2016009896A (es) | 2017-01-11 |
Family
ID=52484559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009896A MX2016009896A (es) | 2014-01-29 | 2015-01-28 | Heteroaril amidas como inhibidores de agregacion de proteina. |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032374B1 (ru) | 2014-01-29 | 2019-05-31 | ЮСиБи БАЙОФАРМА СПРЛ | Гетероарильные амиды в качестве ингибиторов агрегации белков |
| ES2885049T3 (es) | 2015-07-29 | 2021-12-13 | UCB Biopharma SRL | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| CN107625767A (zh) * | 2016-11-25 | 2018-01-26 | 刘淑兰 | 一种治疗慢性盆腔炎的药物 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110167937B (zh) * | 2017-01-26 | 2022-03-29 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的二环双-杂芳基衍生物 |
| US10913735B2 (en) | 2017-01-26 | 2021-02-09 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| WO2018138085A1 (en) | 2017-01-26 | 2018-08-02 | Ucb Biopharma Sprl | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation |
| JP7283699B2 (ja) * | 2017-05-12 | 2023-05-30 | マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体 |
| US11505528B2 (en) | 2017-08-04 | 2022-11-22 | Axial Therapeutics, Inc. | Inhibitors of microbially induced amyloid |
| WO2019089640A1 (en) * | 2017-10-31 | 2019-05-09 | Loma Linda University | Methods for treating traumatic brain injury |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| US20250074902A1 (en) | 2021-12-27 | 2025-03-06 | Shanghai Jingxin Biomedical Co., Ltd. | Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor |
| GB202213796D0 (en) * | 2022-09-21 | 2022-11-02 | Wista Lab Ltd | Tau aggregation inhibitors |
| CN120265630A (zh) * | 2022-11-02 | 2025-07-04 | Ac免疫有限公司 | 用于诊断tdp-43蛋白质病的新化合物 |
| WO2024184180A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| WO2024184179A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| CN121487929A (zh) * | 2023-06-25 | 2026-02-06 | 上海京新生物医药有限公司 | 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
| BR0316680A (pt) * | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| CN101385722A (zh) * | 2003-02-27 | 2009-03-18 | 乔安妮·麦克劳林 | 预防、治疗和诊断蛋白聚集疾病的方法 |
| DK1697371T3 (da) * | 2003-12-19 | 2007-09-17 | Bristol Myers Squibb Co | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer |
| TW200528455A (en) * | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| KR20070018824A (ko) * | 2003-12-19 | 2007-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클 |
| BR122020017756B1 (pt) * | 2004-08-26 | 2022-02-15 | Pfizer Inc | Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero |
| WO2006032322A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| SE0403119D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | Therapeutic agents |
| JP2009505948A (ja) * | 2005-07-11 | 2009-02-12 | デブジェン エヌブイ | キナーゼ阻害剤としてのアミド誘導体 |
| WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| EA200801838A1 (ru) * | 2006-03-15 | 2009-02-27 | 4ЭсЦэ АГ | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-kB |
| CA2668744C (en) * | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| US8450481B2 (en) * | 2007-06-14 | 2013-05-28 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| JP2013508350A (ja) * | 2009-10-20 | 2013-03-07 | ファイザー・インク | ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール |
| NZ600449A (en) * | 2009-12-16 | 2014-10-31 | Neuropore Therapies Inc | Compound suitable for the treatment of synucleopathies |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
| CA2867175A1 (en) | 2012-03-28 | 2013-10-03 | Neuropore Therapies, Inc. | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| ES2661394T3 (es) | 2012-07-16 | 2018-03-28 | Neuropore Therapies, Inc. | Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas |
| EA032374B1 (ru) | 2014-01-29 | 2019-05-31 | ЮСиБи БАЙОФАРМА СПРЛ | Гетероарильные амиды в качестве ингибиторов агрегации белков |
| ES2885049T3 (es) | 2015-07-29 | 2021-12-13 | UCB Biopharma SRL | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| CN110167937B (zh) | 2017-01-26 | 2022-03-29 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的二环双-杂芳基衍生物 |
| US10913735B2 (en) | 2017-01-26 | 2021-02-09 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
-
2015
- 2015-01-28 EA EA201691529A patent/EA032374B1/ru unknown
- 2015-01-28 HR HRP20180813TT patent/HRP20180813T1/hr unknown
- 2015-01-28 KR KR1020167023810A patent/KR102383038B1/ko active Active
- 2015-01-28 CN CN201580017216.1A patent/CN106132960B/zh active Active
- 2015-01-28 ME MEP-2020-148A patent/ME03800B/me unknown
- 2015-01-28 BR BR112016017344-9A patent/BR112016017344B1/pt active IP Right Grant
- 2015-01-28 UA UAA201609003A patent/UA118209C2/uk unknown
- 2015-01-28 PL PL18156929T patent/PL3348556T3/pl unknown
- 2015-01-28 HK HK17105014.2A patent/HK1231470A1/zh unknown
- 2015-01-28 SM SM20180318T patent/SMT201800318T1/it unknown
- 2015-01-28 SM SM20200376T patent/SMT202000376T1/it unknown
- 2015-01-28 SI SI201530252T patent/SI3099684T1/en unknown
- 2015-01-28 CR CR20160394A patent/CR20160394A/es unknown
- 2015-01-28 PT PT15705417T patent/PT3099684T/pt unknown
- 2015-01-28 HU HUE15705417A patent/HUE040274T2/hu unknown
- 2015-01-28 JP JP2016549488A patent/JP6619741B2/ja active Active
- 2015-01-28 DK DK15705417.2T patent/DK3099684T3/en active
- 2015-01-28 NZ NZ722487A patent/NZ722487A/en unknown
- 2015-01-28 PT PT181569294T patent/PT3348556T/pt unknown
- 2015-01-28 EP EP18156929.4A patent/EP3348556B1/en active Active
- 2015-01-28 RS RS20200827A patent/RS60547B1/sr unknown
- 2015-01-28 PL PL15705417T patent/PL3099684T3/pl unknown
- 2015-01-28 WO PCT/US2015/013263 patent/WO2015116663A1/en not_active Ceased
- 2015-01-28 DK DK18156929.4T patent/DK3348556T3/da active
- 2015-01-28 PE PE2016001285A patent/PE20161393A1/es unknown
- 2015-01-28 AP AP2016009347A patent/AP2016009347A0/en unknown
- 2015-01-28 ES ES18156929T patent/ES2808978T3/es active Active
- 2015-01-28 SI SI201531297T patent/SI3348556T1/sl unknown
- 2015-01-28 AU AU2015211119A patent/AU2015211119B2/en active Active
- 2015-01-28 ES ES15705417.2T patent/ES2675301T3/es active Active
- 2015-01-28 HU HUE18156929A patent/HUE050964T2/hu unknown
- 2015-01-28 EP EP15705417.2A patent/EP3099684B8/en active Active
- 2015-01-28 LT LTEP15705417.2T patent/LT3099684T/lt unknown
- 2015-01-28 MX MX2016009896A patent/MX2016009896A/es active IP Right Grant
- 2015-01-28 LT LTEP18156929.4T patent/LT3348556T/lt unknown
- 2015-01-28 SG SG11201606108RA patent/SG11201606108RA/en unknown
- 2015-01-28 RS RS20180644A patent/RS57533B1/sr unknown
- 2015-01-28 MY MYPI2016001401A patent/MY187450A/en unknown
- 2015-01-28 BR BR122018001892-5A patent/BR122018001892B1/pt active IP Right Grant
- 2015-01-28 CA CA2937967A patent/CA2937967C/en active Active
- 2015-01-28 CN CN201911278647.XA patent/CN111039939B/zh active Active
- 2015-01-28 TR TR2018/09440T patent/TR201809440T4/tr unknown
- 2015-12-29 US US14/983,243 patent/US9738635B2/en active Active
-
2016
- 2016-07-27 IL IL246987A patent/IL246987B/en unknown
- 2016-07-28 SA SA516371579A patent/SA516371579B1/ar unknown
- 2016-07-28 ZA ZA2016/05246A patent/ZA201605246B/en unknown
- 2016-07-28 CL CL2016001918A patent/CL2016001918A1/es unknown
- 2016-07-28 PH PH12016501493A patent/PH12016501493B1/en unknown
- 2016-08-29 EC ECIEPI201670327A patent/ECSP16070327A/es unknown
-
2017
- 2017-08-01 US US15/666,503 patent/US10358443B2/en active Active
-
2018
- 2018-06-15 CY CY20181100630T patent/CY1120348T1/el unknown
-
2019
- 2019-06-04 JP JP2019104159A patent/JP6783900B2/ja active Active
- 2019-06-11 US US16/438,348 patent/US11078196B2/en active Active
-
2020
- 2020-07-14 HR HRP20201107TT patent/HRP20201107T8/hr unknown
- 2020-07-24 CY CY20201100682T patent/CY1123374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501493A1 (en) | Heteroaryl amides as inhibitors of protein aggregation | |
| MX2019007053A (es) | Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas. | |
| MX2019008256A (es) | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. | |
| PH12015502028A1 (en) | Ido inhibitors | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| GEAP201814515A (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
| MY199446A (en) | Compounds and compositions and uses thereof | |
| SG11201608441YA (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2019007054A (es) | Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas. | |
| MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP3501524A4 (en) | USE OF PHYTOSPHINGOSINE-1-PHOSPHATE OR A DERIVATIVE THEREOF AS AN IMMUNE ACTIVATOR OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEMENTIA | |
| HK1202452A1 (en) | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| MA39227B1 (fr) | Amides hétéroaryles comme inhibiteurs de l'agrégation protéique | |
| HK40024508A (en) | Compositions and methods for treating alzheimer's disease | |
| AU2015904411A0 (en) | Compositions and methods for the treatment of Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: UCB BIOPHARMA SPRL |
|
| FG | Grant or registration |